9月22日，博苑股份涨1.41%，成交额2.84亿元。两融数据显示，当日博苑股份获融资买入额2382.65万 元，融资偿还3645.92万元，融资净买入-1263.28万元。截至9月22日，博苑股份融资融券余额合计1.13 亿元。 融资方面，博苑股份当日融资买入2382.65万元。当前融资余额1.13亿元，占流通市值的4.39%。 融券方面，博苑股份9月22日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元。 资料显示，山东博苑医药化学股份有限公司位于山东省寿光市侯镇海洋化工园区新海路与大九路路口北 200米，成立日期2008年8月6日，上市日期2024年12月11日，公司主营业务涉及专业从事精细化学品研 发、生产、销售及资源综合利用的高新技术企业,主营业务包括有机碘化物、无机碘化物、贵金属催化 剂、发光材料、六甲基二硅氮烷等产品的研发、生产、销售,并基于资源综合利用资质与工艺技术优势 开展含碘、贵金属等物料的回收利用业务,为客户提供贵金属催化剂、六甲基二硅氮烷等加工服务。主 营业务收入构成为：碘化物74.56%，特种功能化学品12.79% ...

Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has shown significant price increases this year, with a year-to-date rise of 108.17% as of September 15, 2023, despite a recent decline in trading [1][2]. Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2]. - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The revenue composition of the company includes 74.56% from iodides, 12.79% from specialty functional chemicals, 9.94% from trading, and 2.72% from other sources [2]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 747 million yuan, representing a year-on-year growth of 7.39%, while the net profit attributable to shareholders decreased by 19.09% to 99.04 million yuan [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. Group 3: Stock Performance and Trading Activity - As of September 15, 2023, the stock price was 80.64 yuan per share, with a market capitalization of 10.777 billion yuan [1]. - The stock has experienced a trading volume of 1.17 billion yuan, with a turnover rate of 4.25% [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent net buy of 51.18 million yuan on September 9, 2023 [1].

Group 1 - The core viewpoint of the news highlights the recent stock performance of Baoyuan Co., which experienced a decline of 5.72% on September 4, with a trading volume of 484 million yuan [1] - On September 4, Baoyuan Co. had a financing buy-in amount of 27.75 million yuan and a financing repayment of 99.64 million yuan, resulting in a net financing outflow of 71.89 million yuan [1] - As of September 4, the total margin balance for Baoyuan Co. was 118 million yuan, accounting for 5.84% of its circulating market value [1] Group 2 - Baoyuan Co. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with its main business involving the research, production, and sales of fine chemicals [2] - The company's main revenue sources include iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] - For the first half of 2025, Baoyuan Co. reported a revenue of 747 million yuan, representing a year-on-year growth of 7.39%, while the net profit attributable to shareholders decreased by 19.09% to 99.04 million yuan [2] Group 3 - Baoyuan Co. has cumulatively distributed 88.41 million yuan in dividends since its A-share listing [3]

Group 1: Market Overview - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, with applications in X-ray contrast agents, disinfectants, and LCD/LED screens [2] - The downstream application structure of iodine includes three core areas: X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing, accounting for approximately 63% of global consumption [2] - Major iodine production is concentrated in Chile, Japan, and the USA, which together account for 88% of global sales, with Chilean companies alone contributing 60% [2][3] Group 2: Product Portfolio - The company’s inorganic iodide products include potassium iodide, potassium iodate, sodium iodide, hydrogen iodide, and cuprous iodide, primarily used in pharmaceuticals, pesticides, and optoelectronic materials [4] - The organic iodide product trimethyl iodide is utilized as a protecting agent in pharmaceutical synthesis, particularly in the production of antibiotics [4] Group 3: Competitive Advantages - The company integrates resource recycling with core business, creating a circular economy model that ensures stable supply and low costs [5] - A strong R&D team with over 30 years of industry experience has led to the acquisition of 51 patents, enhancing the company’s technological capabilities [5] - The company maintains a leading market position in iodides and luminescent materials, with established long-term partnerships with renowned clients [5][6] Group 4: Quality and Compliance - A comprehensive quality control system spans procurement, production, and sales, ensuring high-quality products and stable supply [6] - The company adheres to compliance in operations, holding all necessary safety and environmental permits, which fosters customer trust and supports sustainable growth [6]

Group 1 - On August 22, Boyuan Co., Ltd. saw a stock price increase of 8.61% with a trading volume of 598 million yuan [1] - The financing buy amount for Boyuan Co., Ltd. on the same day was 85.204 million yuan, with a net financing purchase of 36.4176 million yuan [1][2] - As of August 22, the total financing and securities lending balance for Boyuan Co., Ltd. was 152 million yuan, accounting for 9.36% of its circulating market value [2] Group 2 - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with its listing date set for December 11, 2024 [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The revenue composition of Boyuan Co., Ltd. includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Group 3 - As of August 20, the number of shareholders for Boyuan Co., Ltd. was 13,200, a decrease of 0.14% from the previous period [3] - The average circulating shares per person increased by 0.14% to 2,524 shares [3] - For the first half of 2025, Boyuan Co., Ltd. achieved an operating income of 747 million yuan, a year-on-year increase of 7.39%, while the net profit attributable to shareholders decreased by 19.09% to 99.0429 million yuan [3] Group 4 - Boyuan Co., Ltd. has cumulatively distributed 88.408 million yuan in dividends since its A-share listing [4]

Group 1 - The core viewpoint of the news is that Hongshang Asset has conducted research on a listed company, Boyuan Co., focusing on its increased R&D investment and technological innovation strategies [1] - Boyuan Co. plans to enhance its R&D capabilities by increasing investment and expanding its R&D team, particularly by attracting high-end technical talent [1] - The company’s main products include inorganic iodides such as potassium iodide, potassium iodate, sodium iodide, and hydrogen iodide, which are used in pharmaceuticals, pesticides, feed, and optoelectronic materials [1] Group 2 - Boyuan Co.'s organic iodide product, trimethyl iodide, is primarily used as a protecting group in organic synthesis, especially in the production of antibiotics [1] - The pricing of iodide products is mainly based on the market price of refined iodine, determined through negotiations with customers [1] - The company is working on a high-end organic iodine and bromine new materials project with an annual capacity of 4,100 tons, which includes products like methyl iodide and dimethyl iodide [1]